23948sdkhjf

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
Tivdak (tisotumab vedotin) has received approval from the Japanese Ministry of Health. This means that the treatment is the first and only antibody-drug conjugate (ADC) to be approved for people living with cervical cancer in Japan.

The approval is based on data from a randomized study showing that the treatment reduces the risk of death by 30 pro...
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration
Utvalda artiklar

Nyhetsbrev

Sänd till en kollega

0.078